NASDAQ:ZGNX - Zogenix Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Zogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $48.87 +0.60 (+1.24 %) (As of 12/13/2019 04:00 PM ET) Add Compare Today's Range$48.00Now: $48.87▼$49.1550-Day Range$42.81MA: $45.90▼$48.8352-Week Range$33.43Now: $48.87▼$56.50Volume409,259 shsAverage Volume556,522 shsMarket Capitalization$2.16 billionP/E RatioN/ADividend YieldN/ABeta1.97 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc and changed its name to Zogenix, Inc in August 2006. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:ZGNX Previous Symbol CUSIP98978L10 CIK1375151 Webhttp://www.zogenix.com/ Phone510-550-8300Debt Debt-to-Equity Ratio0.04 Current Ratio3.00 Quick Ratio3.00Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$9.82 million Price / Sales220.24 Cash FlowN/A Price / Cash FlowN/A Book Value$12.46 per share Price / Book3.92Profitability EPS (Most Recent Fiscal Year)($3.23) Net Income$-123,910,000.00 Net MarginsN/A Return on Equity-31.44% Return on Assets-23.59%Miscellaneous Employees90 Outstanding Shares44,255,000Market Cap$2.16 billion Next Earnings Date2/27/2020 (Estimated) OptionableOptionable Receive ZGNX News and Ratings via Email Sign-up to receive the latest news and ratings for ZGNX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ZGNX Rates by TradingView Zogenix (NASDAQ:ZGNX) Frequently Asked Questions What is Zogenix's stock symbol? Zogenix trades on the NASDAQ under the ticker symbol "ZGNX." How were Zogenix's earnings last quarter? Zogenix, Inc. (NASDAQ:ZGNX) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($6.75) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.05) by $5.70. The firm earned $0.63 million during the quarter, compared to analyst estimates of $0.39 million. During the same period last year, the business earned ($1.08) EPS. View Zogenix's Earnings History. When is Zogenix's next earnings date? Zogenix is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Zogenix. What price target have analysts set for ZGNX? 11 analysts have issued 12-month price targets for Zogenix's stock. Their forecasts range from $48.00 to $71.00. On average, they expect Zogenix's stock price to reach $59.70 in the next year. This suggests a possible upside of 22.2% from the stock's current price. View Analyst Price Targets for Zogenix. What is the consensus analysts' recommendation for Zogenix? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zogenix. What are Wall Street analysts saying about Zogenix stock? Here are some recent quotes from research analysts about Zogenix stock: 1. According to Zacks Investment Research, "Zogenix is a specialty biopharmaceutical company focused on developing therapies for patients with rare central nervous system conditions that have limited or no treatment options. The company is currently pursuing two therapies targeting the Dravet Syndrome and the Lennox-Gastaut Syndrome. " (11/3/2019) 2. Northland Securities analysts commented, "We note that 1504 demonstrated 63% and 54% reductions in mean monthly convulsive seizure frequency, versus comparator arms that excluded or included stiripentol therapy, respectively. FINTEPLA was also shown to significantly extend seizure free intervals to ~1 month, with an exceptionally high response rate >70%." (7/8/2019) 3. Mizuho analysts commented, "We gave consideration to (70% PoS). DCF: We assumed a 13% discount rate and a terminal value of 4.5x our estimated 2028 FCF of $861 mil. EV/Sales: we apply a 8x multiple to discounted 2025 sales of $352 mil. the U.S. market, we assume 4Q19 launch and peak market share of 75% (among new therapies) in 2028, equivalent to $526mn in peak sales; for EU and Japan, we assume late 2021 and late 2022 launches. For LGS, we project peak market penetration of 14% in 2028 in the U.S and PoS adjusted sales of $463mn." (3/19/2019) Has Zogenix been receiving favorable news coverage? News stories about ZGNX stock have trended positive on Friday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Zogenix earned a daily sentiment score of 2.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Zogenix. Who are some of Zogenix's key competitors? Some companies that are related to Zogenix include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR) and Pacira Biosciences (PCRX). What other stocks do shareholders of Zogenix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zogenix investors own include GW Pharmaceuticals PLC- (GWPH), Vanda Pharmaceuticals (VNDA), QUALCOMM (QCOM), Gilead Sciences (GILD), Celgene (CELG), Southwest Airlines (LUV), AbbVie (ABBV), Alibaba Group (BABA), Canopy Growth (CGC) and NVIDIA (NVDA). Who are Zogenix's key executives? Zogenix's management team includes the folowing people: Dr. Stephen J. Farr, Co-Founder, CEO, Pres & Director (Age 60)Mr. Michael P. Smith, Exec. VP, CFO, Treasurer & Sec. (Age 51)Dr. Bradley S. Galer, Exec. VP & Chief Medical Officer (Age 57)Dr. Gail M. Farfel, Exec. VP & Chief Devel. Officer (Age 55)Mr. Ashish M. Sagrolikar, Exec. VP & Chief Commercial Officer Who are Zogenix's major shareholders? Zogenix's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Scopia Capital Management LP (3.61%), State Street Corp (2.25%), Eagle Asset Management Inc. (2.14%), Pictet Asset Management Ltd. (0.97%), Emerald Advisers LLC (0.75%) and Point72 Asset Management L.P. (0.75%). Company insiders that own Zogenix stock include Bradley S Galer, Cam L Garner, Erle T Mast, Gail M Farfel, James B Breitmeyer, Life Sciences Maste Perceptive, Mark C Wiggins, Michael P Smith, Renee P Tannenbaum, Roger Hawley and Stephen J Farr. View Institutional Ownership Trends for Zogenix. Which institutional investors are selling Zogenix stock? ZGNX stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Pictet Asset Management Ltd., Barclays PLC, Great West Life Assurance Co. Can, State Street Corp, Rhumbline Advisers and Tower Research Capital LLC TRC. Company insiders that have sold Zogenix company stock in the last year include Cam L Garner, Gail M Farfel, James B Breitmeyer, Mark C Wiggins, Michael P Smith, Renee P Tannenbaum, Roger Hawley and Stephen J Farr. View Insider Buying and Selling for Zogenix. Which institutional investors are buying Zogenix stock? ZGNX stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Scopia Capital Management LP, State of New Jersey Common Pension Fund D, GW&K Investment Management LLC, California Public Employees Retirement System, Chicago Equity Partners LLC, Bluefin Trading LLC and Eagle Asset Management Inc.. Company insiders that have bought Zogenix stock in the last two years include Bradley S Galer and Life Sciences Maste Perceptive. View Insider Buying and Selling for Zogenix. How do I buy shares of Zogenix? Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Zogenix's stock price today? One share of ZGNX stock can currently be purchased for approximately $48.87. How big of a company is Zogenix? Zogenix has a market capitalization of $2.16 billion and generates $9.82 million in revenue each year. The company earns $-123,910,000.00 in net income (profit) each year or ($3.23) on an earnings per share basis. Zogenix employs 90 workers across the globe.View Additional Information About Zogenix. What is Zogenix's official website? The official website for Zogenix is http://www.zogenix.com/. How can I contact Zogenix? Zogenix's mailing address is 5959 Horton Street Suite 500, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected] MarketBeat Community Rating for Zogenix (NASDAQ ZGNX)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 429 (Vote Outperform)Underperform Votes: 318 (Vote Underperform)Total Votes: 747MarketBeat's community ratings are surveys of what our community members think about Zogenix and other stocks. Vote "Outperform" if you believe ZGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZGNX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/13/2019 by MarketBeat.com StaffFeatured Article: Profit Margin
